Stockscreener 앱 받기
0.8758
1.84%
0.0158
시간 외 거래:
.88
0.0042
+0.48%
Brainstorm Cell Therapeutics Inc 주식(BCLI)의 최신 뉴스
Brainstorm Cell Therapeutics adjusts quorum requirement By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm seeks FDA OK to launch NurOwn Phase 3b trial in ALS - ALS News Today
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
BrainStorm advances ALS therapy with FDA trial submission By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
BrainStorm advances ALS therapy with FDA trial submission - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - Nasdaq
BrainStorm Cell Therapeutics (BCLI)Fundamentals Update 09042025 - Research Tree
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World
5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript - Insider Monkey
BrainStorm Cell Therapeutics Reports 2024 Financial Results - TipRanks
BrainStorm Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting - Investing.com Canada
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting By Investing.com - Investing.com South Africa
Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-K Report - TradingView
SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - Nasdaq
INVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Monday - Defense World
Brainstorm Cell Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Brainstorm Cell Therapeutics gains extension from Nasdaq - Investing.com
Brainstorm Cell Therapeutics gains extension from Nasdaq By Investing.com - Investing.com UK
BrainStorm Cell Therapeutics Granted Compliance Extension from N - GuruFocus.com
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - MarketScreener
BrainStorm Wins Critical Nasdaq Extension: New ALS Study and Strategic Plans Unveiled - Stock Titan
BrainStorm receives Nasdaq listing extension to June 30 - Investing.com
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update - The Malaysian Reserve
Strategic Move: Elicio Strengthens Leadership Team Ahead of Crucial Phase 2 Trial Results - Stock Titan
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN
Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Contrast - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - Defense World
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics Inc. to Host Earnings Call - ACCESS Newswire
Brainstorm Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expands By 21.3% - Defense World
Innovations in Stem Cell Therapy Market: Transforming - openPR
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
1.75%
2.22%
자본화:
|
볼륨(24시간):